Journey Medical (DERM) Equity Average (2020 - 2026)

Journey Medical has reported Equity Average for 7 years, with the latest figure at $31.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 50.64% year-over-year to $31.3 million; the trailing twelve-month figure through Mar 2026 stood at $31.3 million (up 50.64% YoY), and the FY2025 full-year result was $26.0 million, up 28.46% from the prior year.
• Equity Average for Q1 2026 stood at $31.3 million, up from $28.9 million in the prior quarter.
• The five-year high for Equity Average was $41.7 million in Q1 2022, with the low at $3.7 million in Q2 2023.
• Historically, Equity Average has averaged $20.9 million across 5 years, with a median of $20.4 million in 2025.
• Annual changes were most pronounced in 2022 — Equity Average soared 664.24% — and 2023, when it tumbled 90.17%.
• Journey Medical's Equity Average stood at $21.6 million in 2022, then declined by 12.61% to $18.9 million in 2023, then decreased by 17.84% to $15.5 million in 2024, then soared by 86.32% to $28.9 million in 2025, then gained by 8.54% to $31.3 million in 2026.
• The last three Equity Average figures came in at $31.3 million (Q1 2026), $28.9 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.